This week marks Xeltis’ 10th Anniversary: a milestone on the company’s roadmap towards developing the first-ever bioabsorbable heart valves and blood vessels designed to enable Endogenous Tissue Restoration (ETR).
“It is poignant that our 10th anniversary milestone coincides with the preparation of clinical trials for our pulmonary valve, our first commercial product,” stated Xeltis CEO, Laurent Grandidier. “It allows us to realize how much progress we have made in the past few years and how future opportunities for Xeltis are much closer now. Today we also celebrate the original Xeltis team who pioneered our project 10 years ago, to whom we are very grateful, as we continue to build upon their legacy.”
Learn more about Xeltis
